eBook

What Reporting Data are Top Pharma R&D and BD Teams Tracking?

The state of reporting in pharma in 2021.

Every company has a strategic vision and a plan to execute against that vision. Pharma companies track their progress with reports - but not every company reports on the same targets, to the same people, or with the same frequency.

In 2021, Inova conducted interviews and collected survey data from more than 60% of the world’s Top Pharma companies to learn what reporting tools they used, what key performance indicators (KPIs) they tracked, and the reporting rhythms they kept.

What Reporting Data are Top Pharma R&D and BD Teams Tracking -illustration-01-03

Please complete the form below

All fields marked with a * are required.
Inova_What Reporting Data are Top Pharma R&D and BD Teams Tracking1
Inova_What Reporting Data are Top Pharma R&D and BD Teams Tracking2
Inova_What Reporting Data are Top Pharma R&D and BD Teams Tracking3
Preview eBook

Learn who is tracking:

  • Asset and Asset Assessments: Pharma companies track the progress of all assets and while there are rarely goals set for the speed at which the asset evaluations move forward, speed is valued.
  • Asset Types and Progress: Regular reporting on the state of discussions and evaluation of those assets in the pipeline was closely tracked.
  • Report Target: Within a team, up the line, Heads of Department, and Executives. Different reports are intended for different audiences at Top Pharma companies.

Resources you may be interested in

Landscaping

Uncover The Best Opportunities In Your Therapeutic Area

Read use case
Dealforma-Dealmaker-LinkedIn-Article

Biopharma Dealmaking Trends & Transformation 2021

Read article
5-Keys-to-Optimizing-hero-1

5 Keys to Optimizing Biopharma Business Development

Download whitepaper

About Inova

Inova accelerates the find, deal, and collaborate phases of biopharma partnering. Its market-leading platform is used by 60% of the world’s top 50 pharma companies to source and manage their opportunities efficiently, and its technology powers more than 50,000 partnering meetings each year at the world's most important biopharma partnering conferences, including the BIO International Convention.
With subsidiaries Labiotech and IN-PART, Inova reaches more than 100,000 readers in life sciences a month and connects a network of 6,500 industry players and academic organizations.